News
Eli Lilly is the first pharma company to take first place in both categories in the eight years that intelligence firm IDEA Pharma has put out its analysis. Skyrocketing sales and multiple FDA approvals helped the company shoot to the top.
FEATURED STORIES
While the pathogen appears unlikely to trigger a pandemic, analysts see potential for Moderna to build goodwill amid a period of political pressure on vaccine manufacturers.
Clinical trial setbacks have limited the near-term opportunities for some of Daiichi Sankyo’s ADCs but the drug developer is betting near-term readouts will catapult it into the top tier of oncology companies in the coming years.
BioSpace analyzed the pay ratio across 10 major pharmaceutical companies to determine which CEOs were paid the most relative to typical employees. J&J, Eli Lilly and Pfizer once again topped the list.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
The Department of Health and Human Services is spinning its wheels, unable to establish steady leadership at three major divisions—the CDC and the FDA’s two primary review units.
THE LATEST
The agreement with Merck brings $290 million upfront to Orion to access the latter’s investigational candidate, ODM-208, for mCPRC and other related drugs.
Aviv Clinics reported data from a study that suggests hyperbaric oxygen therapy may alleviate long COVID symptoms, particularly those associated with cognition.
Gossamer Bio sold shares of its common stock to pave its runway through mid-2024 while Teva and AbbVie reach deals in opioid settlements.
A multinational research collaboration has developed a new peptide dubbed “PATAS”, which appears to fix the metabolic abnormalities leading to type 2 diabetes (T2D).
Early data from Amgen’s ongoing trial on Lumakras for non-small cell lung cancer hinted at positive results from what could be a transformative combination of drugs versus cancer.
BioSpace takes a look at some of the recent legal battles and settlements related to the opioid epidemic across the industry.
An NIH-sponsored trial assessing a combination of Humanigen’s lenzilumab and Gilead Sciences’ remdesivir in hospitalized COVID-19 patients failed to achieve the primary endpoint.
Sanofi, Certara, Pfizer and Thermo Fisher are facing hiring challenges head-on with a common strategy: upskilling programs. They use these programs to fill open roles while training and retaining existing talent.
In what seems like an unlikely collaboration, Seattle-based Fred Hutchinson Cancer Center (Fred Hutch) is partnering with Amazon to develop cancer vaccines.
Atara announced that it has completed an interim analysis of its Phase II EMBOLD trial for the use of its candidate ATA188 in patients with progressive multiple sclerosis.